ABSTRACT
Lysophosphatidic acid (LPA) as a bioactive phospholipid signaling mediator is emerging as an important regulator of endothelial cell functions and angiogenesis. Many studies have shown that LPA is an active player in regulating the processes of endothelial cell migration, proliferation, and differentiation, all essential in angiogenesis. Through modulating angiogenesis associated gene expression, LPA also promotes pathological angiogenesis. Intriguingly, the angiogenic signaling mechanisms mediated by LPA have been linked to specific G-protein coupled receptors and down stream MAPK including Erk1/2, p38 and JNK, protein kinase D (PKD-1), Rho kinase (ROCK), and the NF-kappa B signaling pathways. LPA regulates angiogenic responses via a complex signaling network, and LPA signaling is integrated and transduced to the nucleus to coordinate the transcription of different angiogenic genes. Investigation of these mechanisms will provide novel and valuable insights into the understanding of endothelial cell biology and angiogenic programs. This knowledge will facilitate designs for better therapies for the ischemic cardiovascular diseases and malignant tumors.
INTRODUCTION
Many phospholipids are involved in a very complex intracellular signaling network through binding target proteins, subsequently inducing a conformational change that is instrumental in passing on signals or in opening an ion channel (1). Lysophosphatidic acid (LPA) is a bioactive phospholipid present in almost all mammalian cells and tissues, and functions as a potent signaling molecule. The variety of LPA functions suggests that this signaling lipid is important in cardiovascular development and diseases, tumor progression, reproductive disorders, osteoarthritis, neuropathic pain and neuropsychiatric disorders, and fibrosis (2).
LPA is produced via different mechanisms (Figure 1 ). It can be produced extracellularly by the action of secretory phospholipase A2 (sPLA2) on microvesicles released from activated cells and lipoprotein oxidation. In plasma, LPA is biosynthesized by thrombin-activated platelets through stimulated release of phospholipases A1 (PLA1), and PLA2. However, the hydrolysis of phosphatidic acids (PAs) by PLA1 and PLA2 to produce LPA is thought to occur mainly inside the cell or in the cell membrane. A well-characterized lysophospholipase D (autotaxin or ATX) produces LPA by removing the choline group from lysophosphatidylcholine in the plasma membrane. In the cardiovascular system, ATX dysregulation contributes to cardiovascular diseases such as atherosclerosis and cardiac ischemia. Elegant reviews have discussed the roles of LPA on differential cell signaling in cardiovascular diseases and malignant tumors (2-4). In this review we will focus on LPA in the regulation of angiogenesis.
Angiogenesis in the adult occurs by sprouting from existing blood vessels, a process that requires EC proliferation and migration and remodeling of extracellular matrix. Abnormal angiogenesis and endothelial cell functions are hallmarks of cancer, ischemic and inflammatory diseases (5-7). Evidence for the role of LPA signaling in angiogenesis is emerging and provocative. LPA itself is proangiogenic, and knocking out some of the LPA receptors will also have an impact on angiogenic processes (8) (9) (10) (11) (12) (13) (14) .
REGULATION OF ANGIOGENESIS ASSOCIATED GENE EXPRESSION
Angiogenesis is associated with the chemokines and growth factors produced from macrophages, neutrophils and other inflammatory cells including MCP-1, IL-8, TNF and VEGF. The NF-κB pathway regulates angiogenesis which may be related to the expression of the gene products (15-17). Actually, LPA can regulate angiogenesis through altering angiogenic gene expression in a cell type-specific manner (Table 1) . Using granulosalutein cells obtained from women undergoing in vitro fertilization, Chen et al. demonstrated that LPA increases IL-8 and IL-6 expression through LPA receptors and the NF-κB dependent pathway, leading to increased permeability of HUVEC monolayer (18). These angiogenic properties are also primed by LPA through induction of the expression of granulocyte-monocyte colony stimulating factor (GM-CSF), Gro-alpha, MCP-1, and IL-6 in breast cancer cells (17). In human endometrial stromal cells, LPA enhances IL-8 expression, but not VEGF or IL-6, through the LPA 1 receptor via the NF-κB pathway. In human firsttrimester trophoblast cells, LPA also regulates angiogenesis and the innate immune system in the early pregnancy by inducing chemokine production (19).
LPA shares several biological functions with macrophage migration inhibitory factor (MIF), including promotion of tumor cell growth and associated angiogenesis. MIF plays an important role in the immune system as well as in tumorigenesis and angiogenesis (20). LPA actually increases MIF and VEGF expression in a murine colon cancer cell line. The proangiogenic effect of LPA occurs via MIF interaction with VEGF that is accomplished by modulating Ras-MAPK and RasAkt/PI3K signaling (21). Meanwhile, the tumors derived from MIF knockdown colon cells show reduced size (21), implicating MIF-mediated angiogenesis in promoting Studying the role of LPA in the expression of inflammatory cytokines in endothelial cells will help in understanding the role of EC interaction with other cell types including macrophages and leukocytes in the development of angiogenesis. LPA regulates inflammatory responses in human ECs via LPA 1 and LPA 3 receptors by enhancing angiogenic gene expression (23). In HUVECs, LPA upregulates intercellular adhesion molecule-1 (ICAM-1/CD54) expression, which enhances the interaction between leukocytes and the endothelium through a G i -, NF-κB-, and possibly Rac-dependent mechanism (24). The results suggest that LPA may promote wound healing and inflammation. LPA also mediates ICAM-1 and VCAM-1 expression through activating the Rho kinase-NF-κB pathway via LPA 1 , implicating the role of LPA in endothelial barrier integrity and trans-endothelial migration of leukocytes during inflammation (25). Our group showed that LPA promotes angiogenesis by switching off CD36 signaling, an important antiangiogenic pathway in microvasculature (26, 27). This biological effect is mediated by protein kinase PKD-1 via LPA receptors LPA 1 and LPA 3 (26). The human microvascular endothelial cells (HMVECs) appear to express higher level of LPA 3 than LPA 1 (26), which was proposed to be selectively activated by unsaturated LPA species and showed a strong preference for sn-2 versus the sn-1 acyl-LPA regioisomer (28). These studies suggest a role for LPA in inflammatory angiogenesis.
LPA has been recognized as a potent eNOS activator and used to study NO-related responses in endothelial cells and in the nuclear organelles isolated from these cells (29, 30) . The nucleus may indeed function as a potential organelle for LPA intracrine signaling in the regulation of pro-inflammatory and angiogenic gene expression (29, 31) probably via nuclear LPA 1 -mediated signaling and coordinating with nuclear transcription factor peroxisome proliferator-activated receptor (PPARγ) (32) . Therefore, it could be interesting to understand how extracullar LPA communicates with nuclear LPA signaling to regulate EC gene transcription. Understanding this intracellular LPA-mediated nuclear signaling in endothelial cells and angiogenic gene transcription will provide valuable insights into the transcriptional regulation of angiogenesis.
REGULATION OF ENDOTHELIAL CELL PROLIFERATION AND MIGRATION
The endothelial cells that are essential to angiogenesis line the inner surface of the blood vessels. The normal physiological functions of endothelial cells are essential in regulating angiogenesis. LPA has been shown to impact EC functions including proliferation, migration, and modulation of EC inflammatory responses in the vascular system. The ECs possess high plasticity, allowing them to sense and respond to angiogenic signals. In this process, de novo proliferation is an important step. Fibroblast growth factor (FGF) and LPA have convergent signaling that stimulates EC proliferation through their distinct receptors. LPA triggers proliferation of bovine aortic endothelial cells (BAECs) in concentrations lower than those required to stimulate proliferation of human foreskin fibroblasts (33) , indicating that the ECs are more sensitive to LPA. This may result from differences in receptor expression that can be affected by cell density. It has been reported that receptor LPA 3 maximally expresses at low cell density and minimally expresses in dense cell population, which is positively associated with cell proliferation (34) . However, receptor LPA 1 plays a negative role in regulating cell proliferation, and its expression profile is opposite to that of LPA 3 . In human umbilical vein ECs (HUVECs), LPA has been shown to induce stress fiber formation (9) but not proliferation (35, 36 ). Yet, it enhances HUVEC proliferation in an EGFR transactivation-dependent manner (37) . Intriguingly, in human endometrial microvascular ECs, LPA stimulates proliferation and capillary tube formation by inducing IL-8 from trophoblasts (19). These results suggest that LPA regulates angiogenesis via modulating EC growth in an endothelial cell type and stimulant dependent manner.
EC migration is another essential character for angiogenesis. LPA acts directly on the ECs to regulate cell migration. However, it appears that EC migration in response to LPA is restricted to specific conditions. LPA only stimulates migration of certain ECs on certain extracellular matrix proteins. In fetal bovine heart ECs, LPA stimulates cell migration on a fibronectin matrix by remodeling the cytoskeleton. This may require a balance between Gi and Rho signaling over a broad dose range, whereas VEGF or FGF-2 can induce HUVEC migration over a narrow dose range, producing a bell-shaped curve (38, 39) . In bovine pulmonary artery ECs (BPAECs), LPA regulates migration by recruiting hydrogen peroxide-inducible clone 5, a paxillin family member, to the focal adhesions and to the pseudopodia. This is accomplished via activating MAPK/Erk1/2 pathway (40) . In the absence of a gradient, LPA still increases migration, showing its chemokinetic feature with a small chemotactic component, similar to FGF-2 (38, 39) . This is different from VEGF-induced migration, which is primarily chemotactic. On the contrary, HUVECs, bovine adrenal microvascular ECs, bovine lung microvascular ECs, and BPAECs do not respond significantly to LPA in terms of migration (38, 39) . Furthermore, LPA does not induce a directional migration (chemotaxis) in HUVECs (35, 36) , or in primary human microvascular endothelial cells (HMVECs) (26).
Mechanistically, MAPK/Erk1/2 signaling does not appear to be involved in LPA-stimulated migration in certain EC types. Instead, the Gi-mediated pathway, which diverges upstream from Mek-1, and a balance between Rho and Gi activation is critical for this process (38) . Our own results indicate that LPA regulates EC migration indirectly as it attenuates TSP-1 inhibition of migration stimulated by FGF-2 (33). This is attributed to suppressing CD36 transcription in HMVECs, in which PKD-1 signaling is involved (26). VEGF can induce ATX expression, and consequently LPA and LPA 1 receptor production, via VEGFR-2 in HUVEC (41). ATX and VEGF cooperation may regulate EC migratory responses via Akt2 (41). In addition, through stimulating IL-8 protein expression in trophoblasts, LPA indirectly promotes migration in human endometrial microvascular Ecs (19). Finally, LPA also appears to upregulate VEGFR-2 expression in the microvascular ECs (our unpublished data) that may lead to tip cell positioning (42) , an important step for proangiogenic migration and sprouting. Taken together, LPA differentially regulates EC migration in a cell type and matrix-specific manner. Investigation into LPA on endothelial tip cell behavior and relevant signaling pathways involved may add more insights into the biological significance of LPA-induced EC motility in branching morphogenesis.
EMERGING EVIDENCE OF LPA IN ANGIOGENESIS
More and more studies focus on the role of LPA signaling in angiogenesis. Using the chicken chorioallantoic membrane assay, Rivera-Lopez et al. reported that LPA is proangiogenic in vivo in 2008 (43). LPA is also involved in EC capillary tube formation during inflammatory angiogenesis. As a bioactive lipid mediator, it is present in biological fluids during endothelial damage or injury (37) that may be associated with proangiogenesis in wound healing. The long transmembrane isoform of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1-L) promotes branching morphogenesis after monolayer injury, which is related to LPA-induced RhoA activation (44) . LPA produced by mild oxidized LDL accumulates in the lipid-rich core of atherosclerotic plaques. This may be associated with angiogenesis in atherosclerotic lesions (9, 10).
The phenotypes of LPA receptor knockout mice provide further insight into the role of LPA in angiogenesis. A small proportion of Lpar1 −/− and Lpar1
/Lpar2
−/− mice were born with frontal cranial hematomas (11, 14) . In addition, LPA 3 receptor deletion resulted in anomalous spacing and timing of blastocyst implantation with reduced uterine expression of cyclooxygenase-2 (12), an important player in angiogenesis (13) . Most recently, LPA receptor 4 has been associated with vascular and lymphatic development (8) . A subset of LPA 4 -deficient embryos showed dilated blood and lymphatic vessels with impaired recruitment of mural cells.
In the tumor microenvironment, LPA stimulates not only growth and invasion of cancer cells but also angiogenesis. The latter mainly results from regulation of the expression and function of proangiogenic and antiangiogenic factors. Tumor angiogenesis is predominantly driven by VEGF, a proangiogenic growth factor expressed by many solid cancers (45, 46) . LPA induces VEGF expression in a variety of cell types in the tumor milieu. The cancer-derived LPA stimulates VEGF secretion from human adipose tissue-derived mesenchymal stem cells (hASCs). This may be via multiple signaling pathways involving Rho kinase, ERK, PLC, and phosphoinositide-3-kinase (47) . LPA also stimulates proangiogenic VEGF production in peritoneal mesothelial cells (48) . In ovarian cancer cells, the expression of multiple VEGF variants is stimulated by LPA through cMyc and Sp-1 transcription factors independent of HIF-1α (49). In the multiple myeloma cell line, U266, the Burkitt's lymphoma cell line, BJAB, and the chronic lymphocytic leukemia-like cell line I-83, LPA induces VEGF transcription via the activation of c-Jun N-terminal Kinase (JNK) and NF-κB (50) , an important determinant of tumor aggressiveness. In summary, the studies support the essential role of LPA-mediated VEGFs and their receptor production in proangiogenic responses in malignant tumor. The paracrine effect of LPA-LPA 1 -mediated VEGF expression also promotes tumor angiogenesis within the tumor milieu. This may be associated with in vivo differentiation of the human adipose tissue-derived mesenchymal stem cells (hASCs) to carcinoma-associated fibroblasts that produce VEGF (51) . However, the effect can be abrogated by treatment of hASCs with LPA 1 and LPA 3 receptor antagonist, or LPA 1 knockdown in the hASCs.
Altering antiangiogenic signaling can be another way by which LPA regulates angiogenesis. In mouse dermal fibroblasts, LPA downregulates thrombospondin-1 (TSP-1) (52), the first discovered important endogenous antiangiogenic factor in tumor angiogenesis (6, 53) . This is regarded as an important step in the generation of the proangiogenic tumor stroma. Interestingly, in bovine aortic endothelial cells (BAECs), exogenous TSP-1 inhibits the baseline mitogenic activity in response to LPA. Recombinant mouse TSP-2 also inhibits LPA-stimulated BAEC proliferation in a dose range similar to that of TSP-1 (33) . LPA can abrogate the antiangiogenic effect of TSP-1 by suppressing the transcription of CD36, the receptor of TSP-1 and -2 in HMVECs (26). This indicates that LPA may initiate angiogenesis by counteracting the inhibitory effect of TSPs through a feedback mechanism in the microvasculature.
Studies in ATX, a motility stimulating protein and key enzyme in the production of LPA, also support the role of LPA in tumor angiogenesis. ATX was originally identified as an autocrine factor present in melanoma cell culture medium that stimulated tumor cell motility (54) , and demonstrated to promote tumor angiogenesis (41). Recently, a link between ATX expression, LPA, and VEGF signaling has been reported in ovarian cancer cell lines via a positive feedback mechanism. Exogenous VEGF stimulates ATX production, resulting in enhanced extracellular LPA production while the elevated LPA modulates VEGF responsiveness by inducing VEGFR-2 expression through receptor LPA 4 (55). However, PLCγ signaling increases the level of a secreted form of ATX, producing LPA and promoting regression of blood vessels (56) . This may be explained by the fact that LPA-mediated EC motility leads to disorganization/regression of tube formation. Moreover, mice that under-or overexpressed members of this intrinsic destabilization pathway show either delayed or accelerated regression of blood vessels (56) . Therefore, ECs could be instructed to engage a PLCγ-dependent intrinsic destabilization pathway leading to the production of soluble ATX and LPA and inhibiting proliferative diabetic retinopathy and solid tumors growth. Lung cancer and glioblastoma multiforme are highly angiogenic but resistant to antiangiogenic therapy. Linkous et al. employed syngenic glioblastoma and Lewis lung carcinomas cell lines injected subcutaneously in cPLA2α-deficient mice to investigate the effects of cPLA2 expression on tumor growth and vascularity. Their results demonstrated the key regulatory roles of cPLA2 and LPA in tumor angiogenesis, suggesting cPLA2 as a novel molecular target for antiangiogenic therapy in addition to VEGF signaling (57) . Interestingly, cytosolic phospholipase A2α (cPLA2α) is an enzyme that specifically recognizes the sn-2 acyl bond of phospholipids and catalytically hydrolyzes membrane glycerophospholipids to produce LPA (58) . In addition, BrP-LPA, a dual activity LPA receptor antagonist and autotaxin inhibitor, reduces tumor angiogenesis and promotes tumor regression in an engineered three dimensional lung cancer xenograft model (59) . Taken together, these results support LPA as a potential regulator of angiogenesis via different signaling pathways (Figure 2 ).
SUMMARY AND PERSPECTIVE
The biomedical importance of signaling triggered by LPA has become apparent and increasingly significant in the field of cardiovascular biology and oncology. Emerging evidence demonstrates that LPA regulates angiogenic gene expression via different signaling pathways such as intracellular signaling PKD-1, MAPK/Erk1/2, PI3K/Akt, NFκB, or Rho pathway, subsequently impacting EC behavior and the angiogenic process (Figure 2 ). But the roles of LPA in angiogenesis and signaling via its cognate receptors are likely to be species-, tissue-, and cell-specific. In vascular endothelial cells, the field is only beginning to determine the specific biochemical events and mechanisms that are initiated by different LPA receptors. It should be interesting to study the biological outcomes of activation of the individual receptors and integration of intracellular signaling in endothelial cells. An understanding of endothelial-specific cellular and molecular mechanisms of LPA will also allow the development of novel strategies for therapeutic intervention involving angiogenesis. Studies focusing on the molecular signaling signatures of LPA via different receptors and in different endothelial cell types will aid in deciphering the cues involved and in the optimization of therapeutic approaches.
Phospholipids including LPA may be involved in major components of a complex intracellular signaling network in the ECs. Recently, Bot et al. showed that LPA homeostasis is altered during atherosclerotic progression, favoring intracellular LPA accumulation in carotid artery plaques (10) . Receptor LPA 1 localizes at the nucleus and LPA is able to bind to PPARγ for the regulation of gene expression (29, 32) . It would be of interest to study how LPA functions as an intracellular messenger to couple intracellular signals to nuclear components including transcription factors, co-repressors, and co-activators to modulate specific angiogenic gene transcription. Moreover, LPA may also regulate gene transcription via modification of chromatin structure through epigenetic mechanisms.
Sufficient evidence demonstrates the role of LPA signaling in EC functions and interactions with leukocytes, expression of angiogenic gene transcription and in regulation of angiogenic processes. This highlights the importance of LPA in vascular biology. LPA production and the LPA receptor subtypes expressed by different cell types in the vascular system are important potential drug targets for manipulating pathological angiogenesis and thrombosis (60) . However, the mechanistic role of LPA in angiogenesis has only started to be appreciated, with many Future studies are needed to address these interesting and challenging questions that could lead to better understanding of the roles of LPA in the cardiovascular system and tumor angiogenesis. Regulation of LPA signaling may reveal potential therapeutic targets in cardiovascular diseases and malignant tumors, as well as the cardiovascular complications of diabetes.
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